Table 2.
Comparison of mutational profiles in pathological subtypes of thyroid carcinoma.
| Pathological Subtypes of Thyroid Cancer | PTC-TCGA (n = 402) |
Aggressive Variant PTC (n = 36) |
PDTC-MSKCC (n = 84) |
ATC-MSKCC (n = 33) |
|---|---|---|---|---|
| Key pathways and functional groups | 20% | 34% | 20% | 61% |
| HMTs | - | 11% | 7% | 24% |
| KMT2A | 1% | 0% | 4% | 9% |
| KMT2C | 1% | 11% | 2% | 3% |
| KMT2D | 0% | - | 1% | 15% |
| SETD2 | 0.2% | - | 0% | 3% |
| SWI/SNF complex | - | 14% | 6% | 36% |
| ARID1A | 0% | 0% | 1% | 9% |
| ARID1B | 1% | 6% | 4% | 9% |
| ARID2 | 0.2% | 6% | 1% | 3% |
| ARID5B | 0.2% | 0% | 0% | 3% |
| SMARCB1 | 0% | 0% | 0% | 6% |
| PBRM1 | 0% | 0% | 1% | 6% |
| ATRX | 0.2% | 3% | 0% | 6% |
| PI3K/AKT/mTOR pathway | 5% | 11% | 11% | 39% |
| PIK3CA | 0.4% | 0% | 2% | 18% |
| PTEN | 1% | 0% | 4% | 15% |
| PIK3C2G | 0.2% | 0% | 1% | 6% |
| PIK3CG | 0.2% | 0% | 1% | 6% |
| PIK3C3 | 0% | - | 1% | 0% |
| PIK3R1 | 0.2% | - | 1% | 0% |
| PIK3R2 | 0.2% | - | 0% | 3% |
| AKT1 | 0.6% | 3% | 0% | 0% |
| AKT3 | 1% | 3% | 1% | 0% |
| TSC1 | 0.8% | - | 1% | 0% |
| TSC2 | 0.2% | 0% | 0% | 3% |
| MTOR | 0% | 0% | 1% | 6% |
Abbreviations: TCGA, The Cancer Genome Atlas; PTC: papillary thyroid carcinoma; PDTC, poor differentiated thyroid carcinoma; ATC, anaplastic thyroid carcinoma; HMTs, histone methyltransferase; SWI/SNF, switch/sucrose nonfermenting; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B(PKB/AKT); mTOR, mammalian target of rapamycin.